Resources
42 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 2/20/2024 (updated 3/28/2024)
Early exposure to Adverse Childhood Experiences (ACEs), (e.g., parental substance use) increases the likelihood of future substance use and drug overdose, resulting in an intergenerational cycle of substance-related ACEs.
Posted 6/8/2023 (updated 3/27/2024)
There are multiple systems that can help individuals to address substance use disorder (SUD). A new report from the Addiction and Public Policy Initiative of the O’Neill Institute for National and Global Health Law at Georgetown Law Center discusses how these multiple systems are often disjointed which creates barriers for those needing to access services for SUD.
Posted 1/31/2023 (updated 3/27/2024)
The National Survey on Drug Use and Health (NSDUH) is conducted annual and provides nationally representative data on the use of substances (tobacco, alcohol, and drugs), substance use disorders, those who received substance use treatment, and mental health issues and services. This survey is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA).
Posted 7/27/2022 (updated 3/27/2024)
This presentation will focus on the relationship between trauma and substance use as it relates to treatment for women, as well as a discussion of impactful trauma-informed and gender-responsive interventions. The evidence-based interventions will be based on Seeking Safety and Finding Your Best Self models, both of which are present-focused and easily implemented in any treatment setting.
Posted 7/25/2022 (updated 3/27/2024)
Researchers used claims and enrollment data from Tennessee’s Medicaid program to develop an algorithm measuring five types of ACEs: maltreatment and peer violence, foster care and family disruption, maternal mental illness, maternal substance use disorder, and abuse of the mother. Recent recommendations from the National Advisory Committee on Rural Health & Human Services included stronger data collection that analyzes rural-urban differences.
Posted 6/7/2022 (updated 3/27/2024)
This session highlighted the ways in which data from RCORP consortia are used, how service capacity and access have changed, and whether there is evidence that the health status of rural residents is improving. Additional data on telehealth utility, COVID-19 vaccination efforts, and drivers of MAT retention were highlighted. (Repeated from Day 1 Session 4A on Tuesday, April 5th).
Posted 6/3/2022 (updated 3/27/2024)
This session highlighted the ways in which data from RCORP consortia are used, how service capacity and access have changed, and whether there is evidence that the health status of rural residents is improving. Additional data on telehealth utility, COVID-19 vaccination efforts, and drivers of Medication-Assisted Treatment (MAT) retention was highlighted.
Posted 4/20/2022 (updated 3/27/2024)
This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.
Posted 3/16/2022 (updated 3/27/2024)
Background: Sharp exacerbations of the US overdose crisis are linked to polysubstance use of synthetic compounds. Xylazine is a veterinary tranquilizer, long noted in the street opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national trends, geographic distribution, and health risks are poorly characterized. Methods: In this sequential mixed-methods study, xylazine was increasingly observed by ethnographers in Philadelphia among drug-sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-present overdose mortality across the US and assessed time trends and overlap with other drugs
Posted 2/9/2022 (updated 3/26/2024)
HRSA and JBS have developed guidance to assist your RCORP data collection and Performance Improvement Measurement System (PIMS) reporting efforts. These measures are pending OMB clearance and are subject to revision. This page contains the RCORP data collection resources for the Psychostimulant Support grantees only.
These documents will be updated as new guidance or data sources are identified. We encourage you to bookmark this page so you have the latest version available. Please send any measure-related questions to your HRSA Project Officer or email: rcorp-eval@jbsinternational.com.